ASH News Daily 2017 - Issue 3 - B-23

ASH News Daily

Monday, December 11, 2017

Page B-23
®

career-

enhancemenT
awardS

ASH Scholars
«« From Page B-22

for generating a crucial arm of
adaptive immunity, the thymus
is extremely sensitive to damage,
which can come in the form of
stress (corticosteroids), infection,
cytoreductive chemotherapy, and
irradiation. However, the thymus
also has a remarkable capacity

for repair. Using the thymus as a
model, the goal of Dr. Dudakov's
research is to elucidate the mechanisms underlying tissue damage
and endogenous regeneration and
apply that knowledge into developing novel therapeutic strategies
that can boost immune function
in patients whose immune system
has been compromised due to cytoreductive conditioning, infection, or age. Dr. Dudakov's first
ASH Scholar Award in 2013 was
instrumental in helping him gain
the experience necessary to secure
a faculty position, and this current
award will provide essential sup-

Visit Booth #2233
and
Product Theater #4
Sunday, Dec 10, 11:30 AM - 12:30

port toward establishing an independent research program.

light on the longstanding mystery
of
steady-state
thrombopoietin
regulation. Recognition of this newly identified physiological feedback
mechanism
illuminates
the
pathophysiology
of platelet diseases such as essential thrombocythemia and immune
thrombocytopenia, and contributes to some understanding of the

Renata Grozovsky, PhD
Dr. Grozovsky is an instructor
in medicine at Harvard Medical
School and an associate physiologist at Brigham and Women's Hospital. Her past work unveiled the
mechanism by which the hepatic
Ashwell-Morell receptor (AMR)
removes desialylated (sialic acid-
depleted) senile platelets and regulates thrombopoietin synthesis in
the liver by recruiting JAK2 and
STAT3 signaling. The identification
of this feedback mechanism sheds

»» ASH SCHOLARS Page B-24

Including pediatric patients with relapsed
or refractory CD33-positive AML

Find out more at

Access and support

MylotargHCP.com

1-877-744-5675

Adverse Cytogenetics: In a subgroup analysis in ALFA-0701, the addition of MYLOTARG to
standard combination chemotherapy did not improve event-free survival in the subgroup
of patients having adverse-risk cytogenetics. For patients being treated with MYLOTARG
in combination with daunorubicin and cytarabine for newly diagnosed de novo AML, when
cytogenetics testing results become available consider whether the potential benefit of
continuing treatment with MYLOTARG outweighs the risks for the individual patient.
Embryo-Fetal Toxicity: MYLOTARG can cause embryo-fetal harm when administered to a
pregnant woman. Advise patients of reproductive potential to use effective contraception during
and for 3 and 6 months following treatment for males and females, respectively. Apprise pregnant
women of the potential risk to the fetus. Advise women to contact their healthcare provider if they
become pregnant or if pregnancy is suspected during treatment with MYLOTARG.
Adverse Reactions: The most common adverse reactions (greater than 15%) were hemorrhage,
infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash,
and mucositis.
Contraindications: Hypersensitivity to MYLOTARG or any of its components. Reactions have
included anaphylaxis.
Please see brief summary of Full Prescribing Information, including BOXED WARNING,
on the following page.
Reference: 1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.
PP-MYL-USA-0115

F:7.625"

Printed in USA/November 2017

T:10"

QT Interval Prolongation: QT interval prolongation has been observed in patients treated
with other drugs containing calicheamicin. When administering MYLOTARG to patients who
have a history of or predisposition for QTc prolongation, who are taking medicinal products
that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain
electrocardiograms and electrolytes prior to the start of treatment and as needed during
administration.

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 3